Equity Profile

ABT

Abbott Laboratories

Health CareHealth Care Equipment$158.2B

Jul16Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, and nutrition products. With a market cap of $149 billion, Abbott plays a crucial role in the health care sector, particularly in areas like diabetes care and cardiovascular health.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$1.28

Revenue

Total revenue will provide insight into overall sales performance and demand for Abbott's products.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1 2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock dropped 6% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report an EPS of $1.28 and revenue of $12.5 billion for Q2 2026. The market is watching closely to see if Abbott can maintain its earnings momentum.

Bull Case

If Abbott exceeds EPS and revenue expectations, it could signal strong demand for its products, leading to a positive market reaction.

Bear Case

Conversely, if Abbott fails to meet expectations or provides weak guidance, it could raise concerns about future growth and profitability.

Key Metrics to Watch

EPS

$1.28

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$12.5B

Total revenue will provide insight into overall sales performance and demand for Abbott's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A strong EPS could indicate effective cost management and robust sales, which are critical for investor confidence.

What guidance will Abbott provide for future revenue growth?

Investors will be looking for insights into Abbott's growth prospects, especially in light of recent market volatility.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Abbott's ability to leverage its diverse product portfolio for growth, especially in emerging markets.

Supporting Evidence

Abbott's recent product launches in diabetes care could drive higher-than-expected revenue.

Historical trends show Abbott consistently beating EPS estimates, indicating potential for another surprise.

Options pricing suggests traders expect volatility, which may not align with a stable growth narrative.

Key Risk

If Abbott's revenue growth outpaces expectations, it could significantly alter market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Abbott can sustain its earnings growth amid rising competition and economic pressures.

Bull Confirmed If

An EPS of $1.30 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $1.26 would raise concerns about profitability and market share.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by about 4.62% on the first day, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 3.34%, reflecting market disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·3 sells

Members

House only

Est. Notional

$6,006.00–$90,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the diabetes care segment.
2Insights into market demand for Abbott's cardiovascular products.
3Management's commentary on cost management strategies.
4Guidance on revenue growth for the upcoming quarters.
5Any potential impacts from regulatory changes in the health care sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$1.28

Revenue

Total revenue will provide insight into overall sales performance and demand for Abbott's products.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1 2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock dropped 6% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report an EPS of $1.28 and revenue of $12.5 billion for Q2 2026. The market is watching closely to see if Abbott can maintain its earnings momentum.

Bull Case

If Abbott exceeds EPS and revenue expectations, it could signal strong demand for its products, leading to a positive market reaction.

Bear Case

Conversely, if Abbott fails to meet expectations or provides weak guidance, it could raise concerns about future growth and profitability.

Key Metrics to Watch

EPS

$1.28

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$12.5B

Total revenue will provide insight into overall sales performance and demand for Abbott's products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A strong EPS could indicate effective cost management and robust sales, which are critical for investor confidence.

What guidance will Abbott provide for future revenue growth?

Investors will be looking for insights into Abbott's growth prospects, especially in light of recent market volatility.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Abbott's ability to leverage its diverse product portfolio for growth, especially in emerging markets.

Supporting Evidence

Abbott's recent product launches in diabetes care could drive higher-than-expected revenue.

Historical trends show Abbott consistently beating EPS estimates, indicating potential for another surprise.

Options pricing suggests traders expect volatility, which may not align with a stable growth narrative.

Key Risk

If Abbott's revenue growth outpaces expectations, it could significantly alter market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Abbott can sustain its earnings growth amid rising competition and economic pressures.

Bull Confirmed If

An EPS of $1.30 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $1.26 would raise concerns about profitability and market share.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by about 4.62% on the first day, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 3.34%, reflecting market disappointment and concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·3 sells

Members

House only

Est. Notional

$6,006.00–$90,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the diabetes care segment.
2Insights into market demand for Abbott's cardiovascular products.
3Management's commentary on cost management strategies.
4Guidance on revenue growth for the upcoming quarters.
5Any potential impacts from regulatory changes in the health care sector.